Papular acrodermatitis of childhood‐like eruption triggered by
            <scp>SARS‐CoV</scp>
            ‐2 vaccination: Report of two cases

Villagrasa-Boli, Pablo; Monte‐Serrano, Juan; Martínez-Cisneros, Sara; García‐Gil, Miguel Fernando; Lapeña-Casado, Alejandro; Cruañes‐Monferrer, Joana; Montes‐Torres, Andrea; Ara‐Martín, Mariano

doi:10.1111/dth.15252

Cited by 4 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For the best of our knowledge, only two cases of paediatric GCS were reported after COVID-19 infection (Table 1): Both developed rash after 3-4 weeks of COVID-19 symptoms and one of them had atopic disease like our patient, 2,4 two other cases of GCS was reported in adults, 5,6 and three cases after COVID-19 vaccination. 3,7 Physio-pathogeny remains unclear: Type IV hypersensitivity and IgE-mediated response was evoked: In fact, those patients presented elevated IgE for the most of them and like for our patient and had atopic diseases. Multisystemic inflammatory syndrome in children (MIS-C) is a post-infectious complication of COVID-19 infection: It includes fever, gastrointestinal distress and many unspecific dermatologic findings.…”

mentioning

confidence: 79%

Gianotti‐Crosti syndrome following COVID‐19 infection

Kahla

Rouatbi

Aounallah

et al. 2023

Acad Dermatol Venereol

View full text Add to dashboard Cite

mentioning

confidence: 79%

Gianotti‐Crosti syndrome following COVID‐19 infection

Kahla

Rouatbi

Aounallah

et al. 2023

Acad Dermatol Venereol

View full text Add to dashboard Cite

“…Several cases of uncommon cutaneous manifestations of vaccines have been reported and are summarized in Supplementary Table 5 . 18 , 21 , 24 , 43 , 51 , 68 , 78 - 105 These include toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS), skin necrosis, angioedema, edematous infiltrated plaques, Sweet syndrome, acute generalized exanthematous pustulosis, erythema multiforme (EM), erythema nodosum (EN), radiation recall dermatitis, papular acrodermatitis, cutaneous lichen planus (LP), new-onset and exacerbation of cutaneous lupus erythematosus (cLE), T-cell predominant cutaneous lymphoid hyperplasia, lichenoid reactions, pityriasis lichenoides et varioliformis Acuta (PLEVA), molluscum contagiosum, cutaneous mucormycosis at the injection site, livedo racemosa, fixed drug eruption (FDE), vulvar aphthae, purpura due to Evan’s syndrome, and dermatomyositis. New-onset psoriasis and vitiligo have also been reported.…”

Section: Narrative Review Of Common and Uncommon Cutaneous Manifestat...mentioning

confidence: 99%

Vesiculobullous and Other Cutaneous Manifestations of COVID-19 Vaccines: a Scoping and Narrative Review

Mahmood

Cyr

et al. 2023

J Cutan Med Surg

View full text Add to dashboard Cite

As coronavirus disease (COVID-19) vaccines continue to be administered, dermatologists play a critical role in recognizing and treating the cutaneous manifestations (CM) associated with the vaccines. Adverse cutaneous reactions of COVID-19 vaccines reported in the literature range from common urticarial to rare vesiculobullous reactions. In this study, we performed a (1) scoping review to assess the occurrences of vesicular, papulovesicular, and bullous CMs of COVID-19 vaccines and their respective treatments, and (2) a narrative review discussing other common and uncommon CMs of COVID-19 vaccines. Thirty-six articles were included in the scoping review, and 66 articles in the narrative review. We found that vesicular, papulovesicular, and bullous lesions are infrequent, reported mostly after the first dose of Moderna or Pfizer vaccines. Eleven of the 36 studies reported vesicular reactions consistent with activation or reactivation of the herpes zoster virus. Most vesicular and bullous lesions were self-limited or treated with topical corticosteroids. Other CMs included injection-site, urticarial or morbilliform reactions, vasculitis, toxic epidermal necrolysis, and flaring of or new-onset skin diseases such as psoriasis. Treatments for CMs included topical or oral corticosteroids, antihistamines, or no treatment in self-limited cases. Although most CMs are benign and treatable, the data on the effect of systemic corticosteroids and immunosuppressive therapies on the immunogenicity of COVID-19 vaccines is limited. Some studies report reduced immunogenicity of the vaccines after high-dose corticosteroids use. Physicians may consult local guidelines where available when recommending COVID-19 vaccines to immunosuppressed patients, and when using corticosteroids to manage the CMs of COVID-19 vaccines.

show abstract

“…[7][8][9] Villagrasa-Boli et al reported two adults that suffered with childhood-like papular acrodermatitis after Comirnaty® vaccination. 10 In the pivotal clinical trials of COVID-19 vaccination in adults the most common cutaneous e148 | LETTER TO THE EDITOR manifestations were local site reactions. Furthermore, a small number of rashes, hypersensitivity reactions, and urticarial have been reported.…”

mentioning

confidence: 99%